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Epithelial ovarian carcinoma is the most lethal gynecological cancer due to its silent onset and recurrence with
resistance to chemotherapy. Overexpression of oncogene c-Myc is one of the most frequently encountered events
present in ovarian carcinoma. Disrupting the function of c-Myc and its downstream target genes is a promising
strategy for cancer therapy. Our objective was to evaluate the potential effects of small-molecule c-Myc inhibitor,
10058-F4, on ovarian carcinoma cells and the underlying mechanisms by which 10058-F4 exerts its actions. Using
MTT assay, colony formation, flow cytometry and Annexin V FITC assays, we found that 10058-F4 significantly
inhibited cell proliferation of both SKOV3 and Hey ovarian cancer cells in a dose dependent manner through
induction of apoptosis and cell cycle G1 arrest. Treatment with 10058-F4 reduced cellular ATP production and
ROS levels in SKOV3 and Hey cells. Consistently, primary cultures of ovarian cancer treated with 10058-F4 showed
induction of caspase-3 activity and inhibition of cell proliferation in 15 of 18 cases. The response to 10058-F4 was
independent the level of c-Myc protein over-expression in primary cultures of ovarian carcinoma. These novel
findings suggest that the growth of ovarian cancer cells is dependent upon c-MYC activity and that targeting
c-Myc-Max heterodimerization could be a potential therapeutic strategy for ovarian cancer.
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Among gynecologic cancers worldwide, epithelial ovar-
ian carcinoma is the leading cause of death and the fifth
most frequent cause of cancer related death across all
cancers in women in the United States. Because ovarian
carcinoma presents nonspecific symptoms and is often
asymptomatic until late stages, the majority of patients
are not diagnosed with ovarian carcinoma until they
suffer from advanced stages of disease development
[1,2]. Platinum/taxane chemotherapy and cytoreductive
surgery have proven effective as primary treatments in
patients with advanced stage ovarian carcinoma, with
a positive initial response in approximately 75-80% of* Correspondence: zhangwy9921@hotmail.com; czhou@med.unc.edu
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unless otherwise stated.patients. However, most patients relapse with lethal,
chemo-resistant ovarian carcinoma [3]. Rapid relapse
and the development of drug resistance are the major
challenges in ovarian cancer treatment that mandate the
development of new adjuvant therapy for epithelial
ovarian cancer.
Genetic alterations and deregulation of oncogene and
tumor suppressor gene expressions are known to correl-
ate with and promote the carcinogenesis of ovarian car-
cinoma. Deregulation of the expression of oncogene c-
Myc is one of the most frequently encountered events
present in epithelial ovarian carcinoma [4]. Myc proteins
are key regulators of cell proliferation, apoptosis, and
differentiation and are thus active across multiple cellu-
lar pathways [5]. Recent studies have provided strong
evidence that c-Myc proteins combine with Max, a com-
mon Myc partner protein, to form heterodimers that
can both bind to DNA and induce transactivation. The
transcriptionally active c-Myc-Max dimer promotestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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in cancer cells through its control on the transcription of
Myc target genes [5,6]. The concurrent disruption of
c-Myc-Max heterotetramerization interferes with the func-
tion/expression of all subsequent downstream target genes,
suggesting that the c-Myc-Max interaction is a promising
molecular target for cancer therapeutics. Small-molecule
c-Myc inhibitor, 10058-F4, is a cell-permeable thiazolidi-
none that specifically disrupts the formation and function
of the c-Myc-Max heterodimer and prevents transactiva-
tion of c-Myc target genes [7]. 10058-F4 exhibits potent
anticancer activities towards liver, prostate, kidney, neuro-
blastoma, multiple myeloma, and lymphoma cells [8-13].
However, there is no evidence regarding the effect of
10058-F4 on ovarian carcinoma in vitro or in vivo. Under-
standing the molecular mechanisms of 10058-F4 in ovarian
carcinoma cells may facilitate the development of im-
proved therapeutic strategies for ovarian carcinoma.
In the present study, we aimed to elucidate the specific
role of 10058-F4 in ovarian cancer cell growth. We used
10058-F4 to inhibit the c-Myc-Max interaction in two ovar-
ian cancer cell lines expressing c-Myc in order to determine
if the inhibition of c-Myc-Max subsequently inhibits cellu-
lar proliferation. This study provides cellular and molecular
evidence for the impact of 10058-F4 on ovarian carcinoma
cells through its inhibition of cell proliferation, and the in-
duction of apoptosis and cell cycle arrest, and it offers the
targeting of the c-Myc-Max interaction as a potential and
viable strategy in ovarian cancer chemotherapy.
Materials and methods
Materials and reagents
10058-F4 (F4, Sigma, St. Louis, MO, USA) was dissolved
in dimethylsulfoxide (DMSO) according the manufac-
turer’s instructions and further diluted to indicated con-
centrations in culture medium before use. SKOV3 cells
were maintained in DMEM RPMI-1640 culture medium
supplemented with 10% fetal calf serum (FCS), 100 U/mL
penicillin, and 100 mg/mL streptomycin. Hey cells were
cultured in RPMI-1640 medium with 5% FBS. Fetal bovine
serum (FBS) was from Invitrogen (Carlsbad, CA, USA).
The Annexin V-FITC Apoptosis Detection kit and Cas-
pase3 Activity Assay kit were purchased from Biovision
(Mountain View, CA, USA). All antibodies were pur-
chased from Cell Signaling (Boston, MA, USA). All other
materials were obtained from Life Technologies or from
Sigma-Aldrich.
MTT assays
Cells (4 × 103) were seeded in 96-well microplates treated
with 10058-F4 as indicated. At 72 hours after incubation,
10 μL/well of 5 mg/mL 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) solution was added
to the microplates. Two hours after MTT treatment, themedium was removed, and formazan crystals were dis-
solved by adding 100 μL dimethylsulfoxide (DMSO) per
well. Cell viability was analyzed by measuring the absorb-
ance at 575 nm using spectrometer plate reader (Tecan,
Morrisville, NC). The number of viable cells was assessed
by the percentage of absorbance of treated cells relative to
that of solvent controls.
Colony formation assays
Colony formation assays were performed as described
[14]. Briefly, Hey and SKOV3 cells growing in log phase
were seeded (3000 cells/well in a 6-well plate) in
complete regular growth medium. Cells were allowed to
adhere for 24 hours, and medium was replaced with
fresh complete regular growth medium containing the
indicated concentrations of 10058-F4. Cells were cul-
tured at 37°C for 10 days, with medium changes every
third or fourth day. Cells were stained with 0.5% crystal
violet, and colonies were counted under microscope.
Cell cycle analysis using image cytometry
Hey and SKOV3 cells were treated with 10058-F4 for
24 hours, and cells were harvested and fixed with 70% (w/v)
ice cold ethanol at 4°C for 1 hour. Fixed cells were
washed twice with phosphate-buffered saline (PBS) and
stained with PBS containing 50 μg/mL propidium iodide
(PI) and 100 μg/mL RibonucleaseA (RNase A). Following a
30 minute incubation in darkness at 37°C, the number of
cells in each cell cycle stage was analyzed using the Cell-
ometer Vision CBA image cytometer (Nexcelom Bioscience,
Lawrence, MA, USA)and FCS Express 4 (De Novo Soft-
ware, Los Angeles, CA, USA). The fluorescence data was
captured using FL1 with filter combination VB-660-502
(EX: 540 nm, EM: 660 nm).
Image cytometric analysis of apoptosis
The annexin V/propidium iodide assay was performed ac-
cording to the manufacturer’s recommendation. Briefly,
SKOV3 and Hey cells were plated into 6-well plates and
incubated for 24 hours with 10058-F4 at indicated doses.
The cells were harvested, rinsed with cold PBS, re-
suspended in 40 ul of binding buffer and then add 5ul
FITC conjugated Annexin-V and 5ul 100 ug/ml PI and in-
cubated for 15 min. at room temperature in the dark. A
total of at least 2000 cells were collected and analyzed by
image cytometry (Nexcelom Bioscience). We used FCS
Express 4 software on the collected data to perform the
image analysis. The fluorescence data was captured using
VB-535-402 for annexin V-FITC (EX: 470 nm, EM:
535 nm) and VB-660-502 EX: 540 nm, EM: 660 nm for PI.
ATP determination assay
The ATP concentration was assessed quantitatively using
the CellTiter-Glo Luminescent cell viability assay purchased
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manufacturer’s instructions. Exponentially growing SKOV3
and Hey cells were seeded at a density of 4 × 103 cells per
well in white opaque 96-well plates in 100 ul of fresh cul-
ture medium containing DMEM without phenol red for
24 hours at 37°C in 5% CO2. Different concentrations of
10058-F4 were added to the culture medium and SKOV3
and Hey cells were incubated at 37°C for 24 hours. Then,
100 ul CellTiter-Glo Reagent was added into each well.
Finally, the luminescence was read with a microplate reader
with an integration time of 1 second per well. The experi-
ments were independently performed three times and each
10058-F4 treatment was performed in triplicate.
Reactive oxygen species (ROS) assay
ROS generation was assessed using an ROS-sensitive
fluorescence indicator DCFH-DA and MitoSox red. To
determine intracellular and mitochondria ROS scaven-
ging activity, SKOV3 and Hey cells (1.0 × 104 cells/well)
were seeded in black 96-well plates. After 24 hours, the
cells were treated with 10058-F4 for 8 hours to induce
ROS generation. After the cells were incubated with
DCFH-DA (20 μM) or MitoSox (10 um) for 30 min., the
fluorescence intensity was measured at an excitation
wavelength of 485 nm and an emission wavelength of
530 nm for DCFH-DA and emission 590 nm for Mito-
Sox using a Tecan spectrometer plate reader.
Caspase-3 activity assay
Caspase-3 activity was detected by using caspase-3 activ-
ity assay kit (Biovision). This assay is a Fluorometric
assay which measures caspase-3 activities. The level of
caspase-3 activity is measured by detection of cleavage
of substrate DEVD-AFC. Briefly, Primary culture cells
(1.5 × 105 cells/well) or ovarian cancer cells (2.5 × 105
cells/well) were seeded in 12 well plates or 6 well plates
and incubated for 24 hours at 37°C. The cells were
treated with 10058-F4 at different concentration for
24 hours and then lysated with lysis buffer. 50 ug cell
lysates was used for measuring caspase-3 activity follow-
ing manufacture instructions. The samples were reading
in 96 well plates at a fluorometric plate reader.
Western blot analysis
Total proteins from SKOV3 and Hey cells were extracted
in lysis buffer (Thermo Fisher Scientific, Rockford, IL) and
quantified using the BCA method. Thirty micrograms of
protein were separated by 12% SDS–PAGE gel. After
transfer in cold room, the polyvinylidene fluoride (PVDF)
membranes (Millipore, Billerica, MA, USA) were incu-
bated overnight at 4°C with the following antibodies:
beta-actin(1:3000; Santa Cruz Biotechnology, Santa Cruz,
CA), cyclin D1(1:1000), CDK4(1:1000), CDK6(1:1000),
p27 (1:1000) and p21(1:1000) (Cell Signaling, Boston, MA,USA). After incubation with peroxidase-coupled anti-
mouse IgG and anti-rabbit IgG (Santa Cruz Biotechnology)
at 37°C for 1 hour, bound proteins were visualized using
ECL (Thermo Fisher Scientific) and detected using x films.
The relative protein levels were calculated based on β-actin
as the loading control.
Primary cell culture of ovarian carcinoma
Primary ovarian carcinoma samples were collected in
the operating room of the Department of Gynecologic
Oncology, Beijing Obstetrics and Gynecology Hospital,
Capital Medical University. Beijing, China. A specific
written informed consent was obtained from patients,
and the study was approved by the Institutional Ethics
Committee of Beijing Obstetrics and Gynecology Hos-
pital, Capital Medical University, Beijing, China. In brief,
the freshly obtained ovarian carcinoma tissues were
washed three times in sterile, cold Hank’s Buffered Salt
Solution (HBSS) to remove blood and secretions, and
then gently minced by scissors in DMEM/F12 medium
containing 10% fetal calf serum (FCS). These tumor cells
were then incubated for 1–2 hours at 37°C in 10 ml
DMEM/F12 supplemented with 0.5% collagenase IA,
0.1% DNase, 100 U/ml penicillin and streptomycin with
occasional shaking. After two centrifugations with PBS
wash, the tumor cells were suspended in DMEM/F12
medium and then diluted to 1 × 105 cells/ml. Aliquots
(100 μl) of tumor cell suspension were plated into 96
well tissue culture plates resulting in approximately 2 ×
104 cells per well. The cells were incubated at 37°C for
24 hours in a 5% CO2 incubator, and then were treated
with various concentrations of 10058-F4 or DMSO. Cell
proliferation was assessed using an MTT assay.
Results
10058-F4 inhibits cell proliferation and colony formation
To investigate the potential inhibition of cell growth by
10058-F4 in ovarian cancer, we first examined the effect of
10058-F4 on cell proliferation and clonogenic survival in
SKOV3 and Hey cells. 10058-F4 induced anti-proliferative
activities in SKOV3 and Hey cells, inhibiting growth
in both cell lines in a concentration-dependent manner
(Figure 1A). The IC50 values of 10058-F4 were 4.4 μmol/L
for SKOV3 and 3.2 μmol/L for Hey, respectively. We
next questioned whether 10058-F4 had an effect on the
colonization ability of the cell lines, considering that
in vitro colony formation assays are excellent indicators of
long term tumor cell survival and enable predictions of
the long term antitumor effects of drugs [15]. We ob-
served that clonogenicity of both cancer lines was reduced
in a concentration-dependent manner after exposure to
10058-F4 for 10 days (Figure 1B). Together, these results
demonstrate suppressive effects of 10058-F4 on the prolif-
eration of ovarian cancer cells.
AC
B
D
Figure 1 10058-F4 inhibits cell proliferation in ovarian cancer cells. SKOV3 and Hey cells were cultured for 24 hours and treated with
F4-10058 as indicated doses in 96 well plates for 72 hours. Cell proliferation was assessed with MTT assay (A). 10058-F4 effect on long term
growth in ovarian cancer cells was assessed through colony-forming assay (B). Western blotting results indicated F4-10058 inhibited c-Myc
protein expression in a dose dependent manner after 36 hours treatment (C and D). *p < 0.05 and **p < 0.01, two-sided student t test.
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of 10058-F4 treatment on c-Myc protein expression.
10058-F4 is known specifically to inhibit the c-Myc-Max
interaction, decrease c-Myc protein expression, and pre-
vent transactivation of c-Myc target genes [9,10]. As we
expected, 10058-F4 treatment for 36 hours induced a
marked decrease in the protein expression of c-Myc in a
dose-dependent manner in both cell lines when com-
pared to the control group (Figure1C and D).
10058-F4 induces cell cycle arrest
To examine the mechanism responsible for 10058-F4-
mediated inhibition of cell growth, Hey and SKOV3 cells
were treated with the indicated concentrations (0–50
uM) of 10058-F4 for 48 hours. The cell cycle was deter-
mined by image cytometry. Our data (Figure 2A and B)
show that, consistent with the growth suppression ob-
served in the MTT and colony formation assays, 10058-
F4 treatment led to an increased accumulation of cellsin the G1 phase and a concomitant decrease in the num-
ber of S phase cells in both cell lines when compared
with the control groups. It has been reported that Myc
overexpression enhances endoreduplication in cancer
cells [16]. We next analyzed the effects of 10058-F4 on
endoreduplication in both cell lines by image cytometry.
However, treatment cells with 10058-F4 did not affect
the percentage of hypertetraploid phase (HTP) in SKOV3
and Hey cells.
To further understand the molecular events under-
lying the observed G1 arrest, we next examined the ef-
fects of 10058-F4 on key regulatory molecules including
Cyclins D1, CDK4 and CDK6 which co-operate to pro-
mote the transition from G1 to S phase. Expression of
CDK4 and CDK6 and Cyclin D1 decreased in 10058-
F4-treated SKOV3 and Hey cells. Because c-Myc gene
antagonizes the activity of cell cycle inhibitors as p21
and p27 through different mechanisms, both proteins
were analyzed by Western blotting in response to
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Figure 2 10058-F4 induced cell cycle G1 arrest in ovarian cancer cells. SKOV3 and Hey cells were treated with 10058-F4 at the indicated
dose for 48 hours and then analyzed for cell cycle distributions by Cellometer (A and B). Western blotting analysis of cyclinD1, CDK4, CDK6, p21,
p27 and β-actin expression in ovarian cancer cells treated with 10058-F4 for 24 hours (C). The alternations of cyclinD1, CDK4, CDK6, p21 and p27
were summarized in D and E. *p < 0.05 and **p < 0.01, two-sided student t test.
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Figure 3 10058-F4 induced apoptosis in ovarian cancer cells. SKOV3 and Hey cells were treated with 10058-F4 at the indicated doses for
24 hours and then analyzed for AnnexinV and PI staining by Cellometer (A and B). The measurement of early and late apoptosis was shown in
C (Hey) and D (SKOV3) at two independent experiments. Hey and SKOV3 cells treated with 10058-F4 for 16 hours were analyzed by Western
blotting using PARP, capspase3, caspase7, BCL-2, MCL-1 and β-actin antibodies (E). The BCl-2 and MaCL-1 were analyzed by Western blotting after
16 hours treatment with 10058-F4. 10058-F4 increased cleaved PARP, caspase3 and caspase7 protein expression (F and G) and decreased BCL-2
and MCL-1 protein expression (H). Caspase-3 activity (I) and cell proliferation (J) were determined by ELISA and MTT assay after the both cells
were treated with Z-VAD-FMK, 10058-F4 or combination for 24 or 48 hours. *p < 0.05 and **p < 0.01, two-sided student t test.
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levels of p21 and p27 protein expression were increased
in a dose dependent manner. These results indicated
that 10058-F4 causes growth inhibition associated with
induction of G1 phase arrest.
10058-F4 induces apoptosis
To verify that 10058-F4 treatment inhibits cell prolifera-
tion by inducing apoptosis, we investigated apoptotic cells
by applying an Annexin-V and PI double staining assay
after a 24 hours treatment. As shown in Figure 3A-D, the
percentage of SKOV3 and Hey cells undergoing early and
late apoptosis significantly increased in a dose-dependent
manner when compared to the control (p < 0.05). We next
determined whether mitochondrial apoptosis pathway
which leads to caspase activation and induces cell death
was involved in 10058-F4-induced apoptosis in ovarian
cancer cells. We treated both cells with the indicated con-
centration of 10058-F4 for 16 hours, and cleaved caspase-
3, caspase-7, and PARP proteins were determined by
Western blotting using antibodies that specifically detect
the cleave forms of the caspases. We observed a dose-
dependent increase in expression of cleaved caspase pro-
teins in both cell lines in response to 10058-F4. In
addition, we found 10058-F4 reduced BCL-2 and MCL-1
protein expression in a dose dependent manner after
treatment of 10058-F4 for 24 hours (Figure 3E-H).
To further verify the direct role of apoptosis in 10058-
F4-treated ovarian cancer cells, we used pan-caspase in-
hibitor (Z-VAD-FMK) to block caspase activity in both
cell lines and determined whether the cell proliferation
inhibition and caspase-3 activity were changed after
10058-F4 treatment. Pretreatment with Z-VAD-FMK re-
sulted in total blocking of 10058-F4 induced caspase-3
activity and a significant decrease in the inhibition of
10058-F4-mediated proliferation in both cells (Figure 3I
and J), suggesting that inducing mitochondrial apoptosis
may be a major mechanism to inhibit cell proliferation
in 10058-F4 treated ovarian cancer cells.
10058-F4 decreases Reactive Oxygen Species (ROS) and
ATP generation
Reactive Oxygen Species (ROS) are required for ovarian
cancer cell growth [17]. Myc is known to induce ROS
accumulation. The increase in ROS levels may result insignificant damage to cellular structures and lead to fatal le-
sions in cells that contribute to the inhibition of cell growth.
To evaluate whether targeting c-Myc-Max interaction by
10058-F4 influences the generation of ROS, we assessed
intracellular ROS production with DCFDA in both cell
lines treated with different concentrations of 10058-F4 for
24 hours. As shown in Figure 4A, intracellular ROS con-
centration gradually decreased with increasing concentra-
tions of 10058-F4. Because mitochondrial respiration serves
as a principal source of ROS in most cells, we next exam-
ined whether 10058-F4 affected mitochondria ROS produc-
tion with MitoSox red, which is a new redox-sensitive dye
that is targeted to mitochondria. Treatment with 10058-F4
for 24 hours in both ovarian cancer cells resulted in a sig-
nificant decrease in mitochondria ROS levels (Figure 4B),
suggesting 10058-F4 may inhibit the mitochondrial
electron transport chain through the reduction of the
c-Myc and Max interaction (21). Under the same condi-
tions, we also found a reduced level of cellular ATP pro-
duction in a dose-dependent manner (10–50 uM) in
each cell line after a 24 hour treatment, showing re-
duced levels of ATP production of around 40% and 30%
in Hey and SKOV3 cells, respectively (Figure 4C). Thus
10058-F4 reduced ROS generation and inhibited cellular
ATP production, implicating the relevance of ROS pres-
ence and ATP reduction in the cytotoxicity of 10058-F4
in ovarian carcinoma cells. These results suggest that a
reduction of cellular ATP and inhibition of mitochon-
drial respiration might be involved in cytotoxicity of
10058-F4 in ovarian carcinoma cells.
Cytotoxicity of 10058-F4 in primary cultures of ovarian
carcinoma
To further determine the clinical relevance of 10058-F4,
we examined the effect of 10058-F4 in primary cultures
of ovarian cancer. These tissue samples were obtained
from patients undergoing surgery for primary epithelial
ovarian cancer. After 72 hours of treatment, 15 of the 18
individual patient cultures responded to the 10058-F4
treatment, showing a significant level of cytotoxicity and
inhibition of cell growth. 12 of the 15 sensitive culture
samples exhibited significantly reduced cell proliferation
under 10058-F4 treatment, with wide ranges of IC 50
values from 16–100 μM (Table 1). In order to determine
the relationship between the level of c-Myc protein
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Figure 4 Effect of 10058-F4 on oxidative stress and ATP production in ovarian cancer cells. Hey and SKOV3 cells were treated with
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http://www.translational-medicine.com/content/12/1/226expression and sensitivity to 10058-F4 in each case, we
detected c-Myc protein expression using Western blot-
ting in 18 untreated primary cell cultures. The western
blotting revealed different levels of over-expressed c-
Myc in the 18 primary cultures, and an analysis of the
data using a linear regression model (data not shown)
showed distinct, significant, responses to 10058-F4 inde-
pendent of the precise level of c-Myc protein over-
expression (Figure 5A). The growth of three primary cell
cultures with different expression levels of c-Myc was
not affected by 10058-F4 at a dose of 1–100 uM, sug-
gesting that a higher concentration of 10058-F4 may beTable 1 Pathologic features and inhibition of cell growth
by 10058-F4 in primary culture cells of ovarian carcinoma
Patient ID AGE Diagnosis Stage Grade IC50 (uM) c-MYC
avb 65 Serous IIIA G1 27 Positive
OC2 72 Serous IIIC G3 84 Positive
OC3 48 Serous IIA G1 28 Positive
OC4 36 Serous IC G1 56 Positive
OC5 66 Serous IIIA G1 26 Positive
OC6 61 Mucous IIIA G2 >100 Positive
OC7 55 Serous IIIC G3 N Positive
OC8 51 Serous IIA G3 62 Positive
OC9 69 Serous IIIC G3 >100 Positive
OC10 53 Serous IIIA G1 30 Positive
OC11 38 Mucous IA G1 >100 Positive
OC12 47 Serous IIIC G3 N Positive
OC13 64 Mucous IIIA G1 18 Positive
OC14 66 Serous IIIC G3 N Positive
OC15 62 Serous IIIA G2 >100 Positive
OC16 57 Serous IIIA G1 22 Positive
OC17 43 Serous IIA G3 33 Positive
OC18 51 Serous IIIC G3 16 Positive
18 primary culture cells of ovarian cancer were cultured in 96 well plates or 6
well plates and treated with 10058-F4 as indicated doses. Cell proliferation
was assessed by MTT assay.needed in these three samples or that these cultures may
contain an excess of stromal cells (13). To verify the
apoptotic effects of 10058-F4 in the primary cultures,
caspase-3 activity was determined first with ten primary
cell cultures after a 72 hours treatment. There are no re-
lationships between level of c-Myc protein expression
and caspase-3 activity. No obvious changes of caspase-3
activity in 2 of the primary cell cultures were observed
at concentrations of 10058-F4 up to 100 uM (Figure 5B).
However, the 8 primary cultures that had achievable
IC50 values showed an increase in different levels of
caspase-3 activity, suggesting that the ability of 10058-F4
to inhibit cell proliferation in primary cultures may be
mainly dependent on the induction of apoptosis.
Discussion
Accumulating evidence suggests that the Myc family is
an excellent target for anti-cancer therapeutics due to its
involvement in cell growth, metabolism, proliferation,
apoptosis, and differentiation. Numerous c-Myc target-
ing strategies, including the inhibition of c-Myc expres-
sion or the interruption c-Myc and its downstream
effects, are currently being used in experimental thera-
peutics for several types of cancer [5,18]. Most of these
approaches continue to be hampered by technical diffi-
culties pertaining largely to delivery and the fact that
many c-Myc target genes are functionally redundant
and/or cell type specific [19]. Over the last several years,
several groups have developed small molecular inhibitors
that interfered with the interaction between c-Myc and
Max. These inhibitors restrain not only c-Myc-Max het-
erodimerization but also all subsequent downstream
functions of c-Myc. 10058-F4 is a small molecular in-
hibitor that is composed of a six-member ethylbenzyli-
dine ring and a five-member thioxothiazolidin-4-one. It
specifically inhibits the dimerization of Myc and Max
and prevents the transactivation and expression of the
c-Myc target genes in doses up to 100 uM (13, 19). Sev-
eral studies have confirmed that 10058-F4 significantly
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ovarian cancer. c-Myc protein expression was determined by Western Blotting (A). Caspase-3 activity was determined in ten primary cell cultures
after a 72 hours treatment with 10058-F4 (B).
Wang et al. Journal of Translational Medicine 2014, 12:226 Page 9 of 11
http://www.translational-medicine.com/content/12/1/226inhibited the growth of cancer cells in vitro through the
induction of apoptosis and cell cycle G1 arrest [8-13,20].
A recent animal study has shown treated mice with
10058-F4 for 14 days was sufficient to delay tumor
growth in a neuroblastoma transgenic mouse model and
a xenograft mouse model, These data indicated that
delaying tumor growth in vivo can be achieved by using
a small molecule inhibitor that targets the c-Myc-Max
interaction and targeting c-Myc-Max heterodimerization
might be a good strategy for development of cancer ther-
apy [20]. Although clinical development of c-Myc-Max in-
hibitors, including 10058-F4, is limited by their relatively
low potencies [19], we needed to explore the effect of
targeting the interaction between c-Myc and Max by
10058-F4 on ovarian cancer cells because little or no ad-
vancements have been made in ovarian cancer treatment
over the last thirty years. The present study is the first to
demonstrate that blocking the interaction between c-Myc
and Max by 10058-F4 reduces the viability of ovarian car-
cinoma cells by reducing intracellular ATP and ROS pro-
duction, downregulating c-Myc expression and inducing
apoptosis and cell cycle arrest in ovarian cancer cells. Such
inhibitions in ovarian cancer cells, caused by 10058-F4,
are ultimately consistent with the results of other studygroups [8-13,20]. Our primary result of general toxicity in
mice showed 10058-F4 did not cause obvious toxic effects
when injected 1008-F4 at a dose of 25 mg/kg daily for
5 days (data not shown). These results present further evi-
dence that the c-Myc-Max signaling pathway is essential
to ovarian cancer development and progression and that
the c-Myc-Max interaction may be used as an effective
molecular target for ovarian cancer therapy [7,19,21].
One of the most striking observations in this study is
the sensitivity of the ovarian cancer cells to the anti-
proliferative effects of 10058-F4 despite the variations in
c-Myc protein expression across the ovarian carcinoma
cell lines and primary ovarian carcinoma cells, which is
consistent with Holien’s results in study of multiple mye-
loma [13]. These results clearly pose an interesting pos-
sibility: that the concurrent disruption of c-Myc-Max
heterotetramerization might also interfere with target
gene expression in other ways in various cell types
[19,21]. This result could also account for the heterogen-
eity of primary cultures of ovarian cancer, showing small
portions of stromal cells in some cases in our primary
culture system, and this presence of stromal cells may
affect the viability of and c-Myc function in the ovarian
primary cultures.
Wang et al. Journal of Translational Medicine 2014, 12:226 Page 10 of 11
http://www.translational-medicine.com/content/12/1/226Increased metabolic activity and glucose consumption
in ovarian cancer patients have been linked to ovarian
cancer aggressiveness [22-24]. Cellular ATP levels are a
valuable predictor for chemo-resistance in cancer cells
[25]. The c-Myc oncogene is a major controller of many
aspects of cellular metabolism through the regulation of
genes related to glucose metabolism, glutamine metabol-
ism, and mitochondrial biogenesis [6]. Transgenic mice
with an overexpression of c-Myc in the liver had increased
glycolytic enzyme activity and production of lactic acid in
the liver [26]. Inhibition of c-Myc by SiRNA or small mo-
lecular inhibitors led to the reduction of glucose uptake
and activities of glucose glycolytic enzymes (HKII, LDHA),
all of which ultimately reduce ATP production [27-29].
Overexpression of Myc induces nuclear encoded mito-
chondrial gene expression and biogenesis and increases
the production of mitochondrial ROS [16]. c-Myc knock-
down is associated with a reduction in ROS production
and inhibition of autophagy in cancer cells [30]. In agree-
ment with previous studies on ATP reduction through the
inhibition of c-Myc, the metabolic and therapeutic stress
induced by 10058-F4 led to an acute ATP depletion, which
was accompanied by decreased intracellular and mito-
chondrial ROS and ultimately led to the inhibition of cell
growth in ovarian carcinoma cells.
Assessment of chemotherapeutic drug sensitivities using
primary culture cancer cells provides clinically relevant in-
formation for the optimization of the cancer patient’s
treatment [31-33]. In the panel of 18 primary cell cultures
of primary epithelial ovarian carcinoma, inhibition of
cell proliferation was observed in 15 primary cultures after
72 hours of treatment. The level of c-Myc protein expres-
sion in untreated cells from primary cultures was not
associated with sensitivity to 10058-F4 [13]. However,
caspase-3 activity correlated strongly with cellular re-
sponse to 10058-F4 in 10 primary cultures of ovarian can-
cer, suggesting that the induction of apoptosis is a major
action for the small molecular inhibitors that target the
interaction of c-Myc-Max. The results indicated that sup-
pression of c-Myc through the targeting of the c-Myc-
Max heterodimer has broad therapeutic applications in
cancers including ovarian cancer [7,19,20].
Conclusions
Inhibition of the Myc-Max heterodimer resulted in
promising anti-tumor activity in ovarian cancer cell
lines and ovarian cancer primary cultures and led to
metabolic alterations. Efficient and selective inhibition
of c-Myc through the targeting of c-Myc-Max inter-
action is thus a compelling strategy for treatment of
ovarian cancer.
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